Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking for Charity - 2007 -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (95)	1/2/2007 6:45:09 PM
From: Arthur Radley	Respond to of 397

I know there are inquisitive minds that want to know, so I'm saving all the trouble of wading back through the 2005 post. As most know, Rick rolled his 2005 selections into the 2006 contest. However, he has added some new "grist" to the 2007 contest. Dropped: ACAD ARIA COR DYAX PTN VPHM Added: BCRX CYTK EXEL NRGN PCOP Kept: ARNA ARQL KDUS

To: scaram(o)uche who wrote (95)	1/3/2007 7:17:23 AM
From: dr.praveen	Respond to of 397

Amgen gets option for heart failure drug - NYTimes <Hi Rick...Nice to see the CYTK deal today:-) I have a 5% allocation and I own it in real life> NEW YORK, Jan 3 (Reuters) - Biotechnology company Amgen (AMGN.O: Quote, Profile , Research) formed an alliance with Cytokinetics (CYTK.O: Quote, Profile , Research) to gain an option on an experimental drug to treat heart failure, The New York Times reported on Wednesday. Under the terms of the agreement, which could be announced Wednesday morning, Amgen will pay Cytokinetics $75 million for the option on the drug, which is about to enter the second of three stages of clinical trials, the Times said. The payment would comprise $42 million in cash and the purchase of $33 million in Cytokinetics stock, giving Amgen about 7 percent of the smaller company, the paper added. Amgen would pay $9.47 a share, a 27-percent premium to Cytokinetics' closing price on Friday, the paper said. Cytokinetics could eventually get additional payments of more than $600 million, plus royalties, if the drug reaches the market and has significant sales, the paper also reported. Officials from both companies were not immediately available for comment.